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LETTER Open Access
Primary Care implementation of Germ
Defence, a digital behaviour change
intervention to improve household
infection control during the COVID-19
pandemic: A structured summary of a
study protocol for a randomised controlled
trial
Jeremy Horwood1,2,3* , Melanie Chalder2, Ben Ainsworth4, James Denison-Day5, Frank de Vocht1,2,
Martha M. C. Elwenspoek1,2, Pippa Craggs1, Rachel Denholm1,2, Jonathan Sterne2, Cathy Rice6, Sascha Miller5,
Beth Stuart7, Paul Little7, Michael Moore7, Merlin Willcox7, John Macleod1,2,3, Martin Gullford8, Kate Morton5,
Lauren Towler5, Nick Francis7, Richard Amlôt9 and Lucy Yardley1,2,3,10
Abstract
Objectives: To examine the effectiveness of randomising dissemination of the Germ Defence behaviour change
website via GP practices across England UK.
Trial design: A two-arm (1:1 ratio) cluster randomised controlled trial implementing Germ Defence via GP practices
compared with usual care.
Participants: Setting: All Primary care GP practices in England. Participants: All patients aged 16 years and over who
were granted access by participating GP practices.
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Intervention and comparator: Intervention: We will ask staff at GP practices randomised to the intervention arm
to share the weblink to Germ Defence with all adult patients registered at their practice during the 4-month trial
implementation period and care will otherwise follow current standard management. Germ Defence is an
interactive website (http://GermDefence.org/) employing behaviour change techniques and practical advice on
how to reduce the spread of infection in the home. The coronavirus version of Germ Defence helps people
understand what measures to take and when to take them to avoid infection. This includes hand washing, avoiding
sharing rooms and surfaces, dealing with deliveries and ventilating rooms. Using behaviour change techniques, it
helps users think through and adopt better home hygiene habits and find ways to solve any barriers, providing
personalised goal setting and tailored advice that fits users’ personal circumstances and problem solving to
overcome barriers.
Comparator: Patients at GP practices randomised to the usual care arm will receive current standard management
for the 4-month trial period after which we will ask staff to share the link to Germ Defence with all adult patients
registered at their practice.
Main outcomes: The primary outcome is the effects of implementing Germ Defence on prevalence of all
respiratory tract infection diagnoses during the 4-month trial implementation period.
The secondary outcomes are:
1) incidence of COVID-19 diagnoses
2) incidence of COVID-19 symptom presentation
3) incidence of gastrointestinal infections
4) number of primary care consultations
5) antibiotic usage
6) hospital admissions
7) uptake of GP practices disseminating Germ Defence to their patients
8) usage of the Germ Defence website by individuals who were granted access by their GP practice
Randomisation: GP practices will be randomised on a 1:1 basis by the independent Bristol Randomised Trials
Collaboration (BRTC). Clinical Commission Groups (CCGs) in England will be divided into blocks according to region,
and equal numbers in each block will be randomly allocated to intervention or usual care. The randomisation
schedule will be generated in Stata statistical software by a statistician not otherwise involved in the enrolment of
general practices into the study.
Blinding (masking): The principal investigators, the statistician and study collaborators will remain blinded from
the identity of randomised practices until the end of the study.
Numbers to be randomised (sample size): To detect planned effect size (based on PRIMIT trial, Little et al, 2015):
11.1 million respondents from 6822 active GP practices. Assuming 25% of these GP practices will engage, we will
contact all GP practices in England spread across 135 Clinical Commissioning Groups.
Trial status: Protocol version 2.0, dated 13 January 2021. Implementation is ongoing. The implementation period
started on 10 November 2020 and will end on 10 March 2021.
Trial registration: This trial was registered in the ISRCTN registry (isrctn.com/ISRCTN14602359) on 12 August 2020.
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
Keywords: COVID-19, Randomised controlled trial, Protocol, Primary care, Behaviour change, Digital medicine,
Infection control, Infectious disease, Protection, Digital health
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